ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
EMERYVILLE, Calif., Feb. 22, 2016 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, will present at two upcoming healthcare conferences--
- The 36th Annual Cowen and Company Healthcare Conference
Tuesday, March 8, 2016 at 10:40 a.m. ET
Boston, MA
- The 15th Annual Needham Healthcare Conference
Tuesday, April 12, 2016 at 12:10 p.m. ET
New York, NY
The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events.cfm and available for replay for approximately two weeks after the presentation dates.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc. is driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company is also evaluating ADS-4101, an extended-release version of an FDA-approved single-agent compound for the treatment of epilepsy. The company's portfolio also includes Namzaric™ and Namenda XR®, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. For more information, please visit www.adamaspharma.com.
Namzaric™ is a trademark of Merz Pharma GmbH & Co. KGaA.
Namenda XR® is a registered trademark of Merz Pharma GmbH & Co. KGaA.
For questions, please contact: Susan Lehner Investor Relations & Corporate Communications Adamas Pharmaceuticals, Inc. Phone: 510-450-3567
